William Blair Lowers Earnings Estimates for Simulations Plus

Simulations Plus, Inc. (NASDAQ:SLP) – William Blair lowered their Q1 2026 earnings estimates for Simulations Plus in a report issued on Monday, January 27th. William Blair analyst M. Smock now forecasts that the technology company will earn $0.16 per share for the quarter, down from their previous estimate of $0.17. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share. William Blair also issued estimates for Simulations Plus’ Q2 2026 earnings at $0.31 EPS, Q4 2026 earnings at $0.41 EPS and FY2026 earnings at $1.32 EPS.

A number of other analysts have also weighed in on the stock. Stephens started coverage on shares of Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 target price on the stock. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. BTIG Research cut their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Finally, KeyCorp boosted their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Simulations Plus currently has an average rating of “Moderate Buy” and a consensus target price of $49.40.

Simulations Plus Stock Down 0.1 %

Shares of SLP opened at $33.99 on Wednesday. The company has a market cap of $682.86 million, a P/E ratio of 84.98 and a beta of 0.80. Simulations Plus has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The firm’s 50 day moving average price is $30.19 and its 200 day moving average price is $32.70.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of SLP. Barclays PLC lifted its holdings in Simulations Plus by 390.6% in the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after acquiring an additional 22,669 shares during the period. Geode Capital Management LLC boosted its holdings in Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after buying an additional 18,924 shares in the last quarter. State Street Corp grew its position in Simulations Plus by 4.7% during the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after buying an additional 28,953 shares during the period. BNP Paribas Financial Markets increased its holdings in Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after buying an additional 32,002 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Simulations Plus by 106.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock valued at $1,517,000 after acquiring an additional 24,371 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the transaction, the director now directly owns 3,442,584 shares of the company’s stock, valued at approximately $109,336,467.84. This represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 19.40% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.